In lung cancer, clinical practice guidelines have already incorporated the use of liquid biopsy for the detection of the Epidermal Growth Factor Receptor (EGFR) T790M mutation in ctDNA, which will determine treatment follow-up [23]. This evidence concerns the gene EGFR and lung carcinoma.